Baidu
map

临床数据统计分析心得

2013-07-01 吴宇川 MedSci原创

    以下是我在近三年做各类计量和统计分析过程中感受最深的东西,或能对大家有所帮助。当然,它不是ABC的教程,也不是细致的数据分析方法介绍,它只是“总结”和“体会”。由于我所学所做均甚杂,我也不是学统计、数学出身的,故本文没有主线,只有碎片,且文中内容仅为个人观点,许多论断没有数学证明,望统计、计量大牛轻拍。关于软件    于我个人而言

    以下是我在近三年做各类计量和统计分析过程中感受最深的东西,或能对大家有所帮助。当然,它不是ABC的教程,也不是细致的数据分析方法介绍,它只是“总结”和“体会”。由于我所学所做均甚杂,我也不是学统计、数学出身的,故本文没有主线,只有碎片,且文中内容仅为个人观点,许多论断没有数学证明,望统计、计量大牛轻拍。关于软件    于我个人而言,所用的数据分析软件包括EXCEL、SPSS、STATA、EVIEWS。在分析前期可以使用EXCEL进行数据清洗、数据结构调整、复杂的新变量计算(包括逻辑计算);在后期呈现美观的图表时,它的制图制表功能更是无可取代的利器;但需要说明的是,EXCEL毕竟只是办公软件,它的作用大多局限在对数据本身进行的操作,而非复杂的统计和计量分析,而且,当样本量达到“万”以上级别时,EXCEL的运行速度有时会让人抓狂。    SPSS是擅长于处理截面数据的傻瓜统计软件。首先,它是专业的统计软件,对“万”甚至“十万”样本量级别的数据集都能应付自如;其次,它是统计软件而非专业的计量软件

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2083051, encodeId=3808208305188, content=<a href='/topic/show?id=27175e76395' target=_blank style='color:#2F92EE;'>#数据统计#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57763, encryptionId=27175e76395, topicName=数据统计)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Mon Dec 09 09:36:00 CST 2013, time=2013-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016683, encodeId=4987201668341, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Wed Dec 25 15:36:00 CST 2013, time=2013-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6064, encodeId=98356064ba, content=well, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbaa85451, createdName=chengcway, createdTime=Tue Aug 20 21:09:00 CST 2013, time=2013-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5993, encodeId=220059936c, content=Want to see, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Eason, createdTime=Tue Aug 06 23:32:00 CST 2013, time=2013-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5902, encodeId=f2255902e3, content=ok, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=505784226, createdName=DrZhu, createdTime=Fri Jul 12 09:59:00 CST 2013, time=2013-07-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2083051, encodeId=3808208305188, content=<a href='/topic/show?id=27175e76395' target=_blank style='color:#2F92EE;'>#数据统计#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57763, encryptionId=27175e76395, topicName=数据统计)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Mon Dec 09 09:36:00 CST 2013, time=2013-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016683, encodeId=4987201668341, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Wed Dec 25 15:36:00 CST 2013, time=2013-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6064, encodeId=98356064ba, content=well, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbaa85451, createdName=chengcway, createdTime=Tue Aug 20 21:09:00 CST 2013, time=2013-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5993, encodeId=220059936c, content=Want to see, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Eason, createdTime=Tue Aug 06 23:32:00 CST 2013, time=2013-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5902, encodeId=f2255902e3, content=ok, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=505784226, createdName=DrZhu, createdTime=Fri Jul 12 09:59:00 CST 2013, time=2013-07-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2083051, encodeId=3808208305188, content=<a href='/topic/show?id=27175e76395' target=_blank style='color:#2F92EE;'>#数据统计#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57763, encryptionId=27175e76395, topicName=数据统计)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Mon Dec 09 09:36:00 CST 2013, time=2013-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016683, encodeId=4987201668341, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Wed Dec 25 15:36:00 CST 2013, time=2013-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6064, encodeId=98356064ba, content=well, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbaa85451, createdName=chengcway, createdTime=Tue Aug 20 21:09:00 CST 2013, time=2013-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5993, encodeId=220059936c, content=Want to see, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Eason, createdTime=Tue Aug 06 23:32:00 CST 2013, time=2013-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5902, encodeId=f2255902e3, content=ok, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=505784226, createdName=DrZhu, createdTime=Fri Jul 12 09:59:00 CST 2013, time=2013-07-12, status=1, ipAttribution=)]
    2013-08-20 chengcway

    well

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2083051, encodeId=3808208305188, content=<a href='/topic/show?id=27175e76395' target=_blank style='color:#2F92EE;'>#数据统计#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57763, encryptionId=27175e76395, topicName=数据统计)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Mon Dec 09 09:36:00 CST 2013, time=2013-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016683, encodeId=4987201668341, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Wed Dec 25 15:36:00 CST 2013, time=2013-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6064, encodeId=98356064ba, content=well, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbaa85451, createdName=chengcway, createdTime=Tue Aug 20 21:09:00 CST 2013, time=2013-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5993, encodeId=220059936c, content=Want to see, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Eason, createdTime=Tue Aug 06 23:32:00 CST 2013, time=2013-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5902, encodeId=f2255902e3, content=ok, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=505784226, createdName=DrZhu, createdTime=Fri Jul 12 09:59:00 CST 2013, time=2013-07-12, status=1, ipAttribution=)]
    2013-08-06 Eason

    Want to see

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2083051, encodeId=3808208305188, content=<a href='/topic/show?id=27175e76395' target=_blank style='color:#2F92EE;'>#数据统计#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57763, encryptionId=27175e76395, topicName=数据统计)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Mon Dec 09 09:36:00 CST 2013, time=2013-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2016683, encodeId=4987201668341, content=<a href='/topic/show?id=75a2228481a' target=_blank style='color:#2F92EE;'>#临床数据#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22848, encryptionId=75a2228481a, topicName=临床数据)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fa4f352, createdName=chenlianhui, createdTime=Wed Dec 25 15:36:00 CST 2013, time=2013-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6064, encodeId=98356064ba, content=well, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bbaa85451, createdName=chengcway, createdTime=Tue Aug 20 21:09:00 CST 2013, time=2013-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5993, encodeId=220059936c, content=Want to see, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=Eason, createdTime=Tue Aug 06 23:32:00 CST 2013, time=2013-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5902, encodeId=f2255902e3, content=ok, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=505784226, createdName=DrZhu, createdTime=Fri Jul 12 09:59:00 CST 2013, time=2013-07-12, status=1, ipAttribution=)]
    2013-07-12 DrZhu

    ok

    0

相关资讯

统计中的悖论

悖论这个词主要是指一切与我们的直觉或日常生活经验相矛盾的结论。悖论这个词由来已久,公元前6世纪古希腊有一句经典的“说谎者悖论”,这句话是“这句话是谎话”。那句话到底是不是谎话?至今仍然无人能给出合理的解释。古希腊的著名诡辩家芝诺提出了几个非常著名的悖论,如“阿基里斯永远追不上一只乌龟”和“飞矢不动”是最为经典的,一直是困扰数学家的难题。 统计中也有悖论,首先说明一个辛普森悖论,它首先是由一个名叫

临床医学数据标准化的几种方法

数据的标准化(normalization)是将数据按比例缩放,使之落入一个小的特定区间。在某些比较和评价的指标处理中经常会用到,去除数据的单位限制,将其转化为无量纲的纯数值,便于不同单位或量级的指标能够进行比较和加权。 其中最典型的就是数据的归一化处理,即将数据统一映射到[0,1]区间上,常见的数据归一化的方法有: min-max标准化(Min-max normalization)

CA Cancer J Clin :2013年美国癌症统计分布报告

每年,美国癌症协会(American Cancer Society)都要对当年全美的癌症新发和死亡病例的预期数据进行估测,并与癌症研究院(NCI)、疾病预防预防与控制中心(CDC)的相关数据——癌症发生率、死亡率、生存率等——进行对比。最终详细数据报告会发表在在影响因子最高的杂志《CA CANCER J CLIN》上。 原文下载:Cancer Statistics, 2013.pdf

临床研究中最小临床意义变化值(MCID)确定方法

目前确定最小临床意义变化值(minimal clinically important difference,MCID)的方法有效标法、分布法、专家意见法和文献分析法。效标法可对所确定的最小临床意义变化值给出专业解释,但没有考虑测量误差, 不同效标会产生不同的最小临床意义变化值,而且通常情况下很难找到合适的效标。分布法考虑了测量误差,易于实施,但不同样本得出的结果可能不同,无法为所 确定的最小可

如何从统计角度来review研究方案

一个临床试验研究方案的撰写,离不开统计,那么对于一个完整的研究方案,从统计角度它应该包括什么内容,或者一个统计师应从那些方面来review呢。1. 必须有具体明确的研究目的。这点勿容置疑,如果你连研究目的和用来证实研究目的的终点指标都没搞清楚,你就别做了,准备洗洗睡吧。。。研究目的是啥?研究 目的就是你做这个试验想要回答的问题。设立正确的研究目的是临床试验最关键的一部分。研究目的一旦确定

ICH E9临床试验的统计学指导原则解析

ICH E9 Statistical principles for clinical trials (临床试验的统计学指导原则)可谓生物统计师的bible,目的在于协调欧洲、日本和美国在进行药品上市申请的临床试验时所应用的统计学方法的指导原则。虽说中国是协调三方之外的国家,SFDA还为此另外制定了自己的《化学药物和生物制品临床试验的生物统计学技术指导原则》,但其内容基本还是照抄翻译了ICH E9的

Baidu
map
Baidu
map
Baidu
map